Cytopathologic diagnosis was suspicious for papillary thyroid carcinoma and ThyroSeq molecular testing revealed an underlying CREB3L2::PPARγ fusion, implying a high risk for “malignancy or non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)”. This evidence concerns the gene CREB3L2 and thyroid gland papillary carcinoma.